Email this article Sovremennye vozmozhnosti lecheniya kolorektal'nogo raka
- Authors: Barsukov Y.A1, Knysh VI1
-
Affiliations:
- НИИ КО ГУ РОНЦ РАМН им. Н.Н.Блохина, Москва
- Issue: Vol 8, No 2 (2006)
- Pages: 7-16
- Section: Articles
- URL: https://bakhtiniada.ru/1815-1434/article/view/26609
- ID: 26609
Cite item
Full Text
Abstract
В структуре онкологической заболеваемости колоректальный рак КРР прочно занимает второе-третье место в большинстве экономически развитых стран мира как у мужчин, так и у женщин. За последние 20 лет рак толстой кишки переместился в структуре онкологической заболеваемости населения Российской Федерации с 6-го на 3-е место. В связи с этим ознакомление врачей общего профиля с клинической картиной КРР и методами диагностики приобретает особую актуальность, тем более что контингент больных раком толстой кишки, состоящий на учете в онкологических учреждениях, увеличился более чем в два раза.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Yu A Barsukov
НИИ КО ГУ РОНЦ РАМН им. Н.Н.Блохина, Москва
V I Knysh
НИИ КО ГУ РОНЦ РАМН им. Н.Н.Блохина, Москва
References
- Vogel I, Soeth E, Ruder C et al. Disseminated tumor cells in the blood and/or bone marrow of patients with colorectal carcinoma are an independent prognostic factor. Ann. Oncol., 2000; 11 (suppl. 4): 43, abstr. 183.
- Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet, 1995 Apr 15;345(8955):939-44.
- Haller D, Catalano P.J, Macdonald J.S, Mayer R.J. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five - year final report of int-0089. Proc Am Soc Clin Oncol 1998; 17: 256a (Abstr 982).
- Wolmark N, Rockette H, Mamounas E et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999; 17: 3553-9.
- Andre T et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol, 2003 Aug 1;21(15):2896-903.
- Grothey A et al. Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms. Med Klin, 2002 May 15;97(5):270-7.
- S. Hensley Alford et al. Stage III colon cancer in the elderly: Adjuvant therapy and survival. Proc Am Soc Clin Oncol 2003 abstr 3008.
- Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-106.
- Hoff P.M, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first - line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-92.
- Cassidy J. et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial. Proceedings ASCO 2004 abstract 3509.
- Twelves C. et al. Capecitabine as adjuvant treatment for satge III colon cancer. N Engl J Med 2005; 352:269-704.
- Joseph N.E et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol. 2003 Apr;10(3):213-8.
- Scheithauer W. et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil - based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial Annals of Oncology 14: 1735-1743, 2003.
Supplementary files
